Literature DB >> 20493606

A physiologic-based approach to the evaluation of a patient with hyperkalemia.

Biff F Palmer1.   

Abstract

Hyperkalemia generally is attributable to cell shifts or abnormal renal potassium excretion. Cell shifts account for transient increases in serum potassium levels, whereas sustained hyperkalemia generally is caused by decreased renal potassium excretion. Impaired renal potassium excretion can be caused by a primary decrease in distal sodium delivery, a primary decrease in mineralocorticoid level or activity, or abnormal cortical collecting duct function. Excessive potassium intake is an infrequent cause of hyperkalemia by itself, but can worsen the severity of hyperkalemia when renal excretion is impaired. Before concluding that a cell shift or renal defect in potassium excretion is present, pseudohyperkalemia should be excluded. Copyright (c) 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20493606     DOI: 10.1053/j.ajkd.2010.01.020

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  14 in total

1.  Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.

Authors:  Pantelis A Sarafidis; Rochelle Blacklock; Eleri Wood; Adam Rumjon; Shanique Simmonds; Jessica Fletcher-Rogers; Rachel Ariyanayagam; Aziza Al-Yassin; Claire Sharpe; Katie Vinen
Journal:  Clin J Am Soc Nephrol       Date:  2012-05-17       Impact factor: 8.237

2.  Serum potassium in dual renin-angiotensin-aldosterone system blockade.

Authors:  Stephen L Seliger; Linda F Fried
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 8.237

3.  A physiologic-based approach to the treatment of acute hyperkalemia.

Authors:  Roman Shingarev; Michael Allon
Journal:  Am J Kidney Dis       Date:  2010-06-08       Impact factor: 8.860

Review 4.  Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management.

Authors:  André Gustavo P Sousa; João Victor de Sousa Cabral; William Batah El-Feghaly; Luísa Silva de Sousa; Adriana Bezerra Nunes
Journal:  World J Diabetes       Date:  2016-03-10

Review 5.  Mineralocorticoid receptor antagonists for cardioprotection in chronic kidney disease: a step into the future.

Authors:  Maria-Eleni Alexandrou; Marieta P Theodorakopoulou; Mehmet Kanbay; Pantelis A Sarafidis
Journal:  J Hum Hypertens       Date:  2022-01-04       Impact factor: 2.877

6.  Potassium Homeostasis, Oxidative Stress, and Human Disease.

Authors:  Udensi K Udensi; Paul B Tchounwou
Journal:  Int J Clin Exp Physiol       Date:  2017

Review 7.  Potassium: friend or foe?

Authors:  Aylin R Rodan
Journal:  Pediatr Nephrol       Date:  2016-05-18       Impact factor: 3.714

Review 8.  Regulation of Potassium Homeostasis.

Authors:  Biff F Palmer
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

9.  Electrocardiogram findings of patients with serum potassium levels of nearly 10.0 mmol/L: a report of two cases.

Authors:  Atsushi Kotera; Hiroki Irie; Shinsuke Iwashita; Junichi Taniguchi; Shunji Kasaoka; Katsuyuki Sagishima; Hidenobu Kamohara; Yoshihiro Kinoshita
Journal:  Acute Med Surg       Date:  2014-05-19

Review 10.  Role of single-pill combination therapy in optimizing blood pressure control in high-risk hypertension patients and management of treatment-related adverse events.

Authors:  Abdul Ali Abdellatif
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-08-13       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.